Quantcast
Last updated on April 18, 2014 at 10:45 EDT

Latest Gene therapy Stories

2013-11-27 23:04:25

Alliance for Cancer Gene Therapy (ACGT) – a Stamford, CT-based non-profit devoted exclusively to treating and eradicating cancer with cell and gene therapies – has provided a $500,000 grant to combat glioblastoma, one of the most difficult types of brain cancer to treat. Visit http://www.ACGTFoundation.org. United States and Canada (PRWEB) November 27, 2013 Alliance for Cancer Gene Therapy (ACGT) – a Stamford, CT-based non-profit devoted exclusively to treating and eradicating...

2013-11-26 08:27:27

Additional Preclinical Studies Demonstrate Potential for Intravenous Administration of Toca 511 and Use in Combination with Temozolomide and Radiation SAN DIEGO, Nov. 26, 2013 /PRNewswire/ -- Tocagen Inc. today announced that interim clinical data from two ongoing Phase I investigational studies presented at the Society for Neuro-Oncology (SNO) Annual Meeting in San Francisco showed that Toca 511 administration followed by courses of oral Toca FC was safe and well tolerated in 60...

2013-11-22 08:23:09

SAN DIEGO, Nov. 22, 2013 /PRNewswire/ -- Tocagen Inc. today announced that six presentations on Toca 511 will be given at the Society of Neuro-Oncology (SNO) Annual Meeting, including interim clinical data from two ongoing Phase I investigational studies, which show that, to date, Toca 511 administration followed by oral courses of Toca FC is safe and well tolerated, and demonstrated antitumor activity in some patients with high grade glioma (HGG). HGG includes glioblastoma multiforme (GBM),...

2013-11-20 16:26:51

RICHMOND, Calif., Nov. 20, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that seven abstracts have been accepted for presentation at the 55(th) annual meeting of the American Society of Hematology (ASH), which will be held December 7-10, 2013, in New Orleans, LA. (Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO) "ASH provides an outstanding forum to highlight our advancing pre-clinical IND-candidate programs," said Edward Lanphier, Sangamo's...

2013-11-19 23:22:53

Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai Report Promising Long-Term Follow-up Results for its Single Dose AAV1/SERCA2a Gene Therapy in Advanced Heart Failure Patients New York, New York (PRWEB) November 19, 2013 Researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai reported the long-term benefits of a single dose of their gene therapy AAV1/SERCA2a in advanced heart failure patients on Nov. 19 at the American Heart...

2013-11-15 08:27:03

Data Demonstrate Long-Term Expression of Functional Nerve Growth Factor in the Brain and Stabilization of Brain Cell Metabolic Activity RICHMOND, Calif., Nov. 15, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today the presentation of positive data from the Phase 1 clinical trial of CERE-110 (AAV-NGF), a gene therapy approach designed to deliver nerve growth factor (NGF) for the treatment of Alzheimer's disease (AD). This novel product was developed by Ceregene,...

2013-11-13 23:03:59

Preclinical Testing at Icahn School of Medicine at Mount Sinai Shows SUMO-1 Gene Therapy Shrinks an Enlarged Heart, Improves Heart Function, and Blood Flow New York, NY (PRWEB) November 13, 2013 Researchers at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai have successfully tested a powerful gene therapy, delivered directly into the heart, to reverse heart failure in large animal models. The new research study findings, published in November 13 issue of...

2013-11-04 08:26:00

Data Demonstrate ZFN-dependent CCR5 Modification of Long-lived Central Memory and Stem-like T-cells RICHMOND, Calif., Nov. 4, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of clinical data from its program to develop a ZFP Therapeutic(®) for HIV/AIDS. The data demonstrate a reduction in the HIV DNA reservoir since receiving SB-728-T in seven of nine HIV-infected subjects on long-term anti-retroviral therapy (ART), despite a median duration of...

2013-11-01 16:23:36

Transposagen Issued Two Key U.S. Patents Covering Gene Editing Technology and Rat Models of Inflammatory & Autoimmune Disease. LEXINGTON, Ky., Nov. 1, 2013 /PRNewswire-iReach/ -- Transposagen Biopharmaceuticals, Inc., based in Lexington, KY, has announced today the issuing of Patent No. 8,399,643 entitled, "Nucleic Acids Encoding Hyperactive PiggyBac Transposases" on March 19th and Patent No. 8,558,055 entitled, "A Genetically Modified Rat Comprising a Cytokine Gene Disruption and...

2013-10-30 15:35:50

Scientists in The Research Institute at Nationwide Children's Hospital have found a way to overcome one of the biggest obstacles to using viruses to deliver therapeutic genes: how to keep the immune system from neutralizing the virus before it can deliver its genetic payload. In a study published recently in Molecular Therapy, researchers found that giving subjects a treatment to temporarily rid the body of antibodies provides the virus safe passage to targeted cells, allowing it to release a...